140 related articles for article (PubMed ID: 17140550)
1. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity.
Gilbert GL; Kim HJ; Waataja JJ; Thayer SA
Brain Res; 2007 Jan; 1128(1):61-9. PubMed ID: 17140550
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
Chen J; Lee CT; Errico S; Deng X; Cadet JL; Freed WJ
Brain Res Mol Brain Res; 2005 Apr; 134(2):215-25. PubMed ID: 15836919
[TBL] [Abstract][Full Text] [Related]
3. Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture.
Lundberg DJ; Daniel AR; Thayer SA
Neuropharmacology; 2005 Dec; 49(8):1170-7. PubMed ID: 16157354
[TBL] [Abstract][Full Text] [Related]
4. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture.
Shen M; Thayer SA
Mol Pharmacol; 1999 Jan; 55(1):8-13. PubMed ID: 9882692
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
6. CRIP1a switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity.
Stauffer B; Wallis KT; Wilson SP; Egertová M; Elphick MR; Lewis DL; Hardy LR
Neurosci Lett; 2011 Oct; 503(3):224-8. PubMed ID: 21896317
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav 2.2 channels.
Koch M; Kreutz S; Böttger C; Grabiec U; Ghadban C; Korf HW; Dehghani F
Hippocampus; 2011 May; 21(5):554-64. PubMed ID: 20135626
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores.
Zhuang SY; Bridges D; Grigorenko E; McCloud S; Boon A; Hampson RE; Deadwyler SA
Neuropharmacology; 2005 Jun; 48(8):1086-96. PubMed ID: 15910885
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
Sim LJ; Hampson RE; Deadwyler SA; Childers SR
J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
11. Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones.
Straiker A; Mackie K
J Physiol; 2005 Dec; 569(Pt 2):501-17. PubMed ID: 16179366
[TBL] [Abstract][Full Text] [Related]
12. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.
Lauckner JE; Hille B; Mackie K
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19144-9. PubMed ID: 16365309
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
14. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture.
Kouznetsova M; Kelley B; Shen M; Thayer SA
Mol Pharmacol; 2002 Mar; 61(3):477-85. PubMed ID: 11854427
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.
Pintor A; Tebano MT; Martire A; Grieco R; Galluzzo M; Scattoni ML; Pèzzola A; Coccurello R; Felici F; Cuomo V; Piomelli D; Calamandrei G; Popoli P
Neuropharmacology; 2006 Oct; 51(5):1004-12. PubMed ID: 16895732
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
17. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
Kim SH; Won SJ; Mao XO; Jin K; Greenberg DA
Mol Pharmacol; 2006 Mar; 69(3):691-6. PubMed ID: 16299067
[TBL] [Abstract][Full Text] [Related]
19. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
